These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18549919)

  • 1. Learning to use a biomarker. More about B-type natriuretic peptide.
    Mills RM
    J Am Coll Cardiol; 2008 Jun; 51(24):2336-8. PubMed ID: 18549919
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
    Nishii M; Inomata T; Takehana H; Naruke T; Yanagisawa T; Moriguchi M; Takeda S; Izumi T
    J Am Coll Cardiol; 2008 Jun; 51(24):2329-35. PubMed ID: 18549918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natriuretic peptides in heart failure: their role in daily practice.
    Loboz-Grudzień K; Jaroch J
    Cardiol J; 2009; 16(1):1-3. PubMed ID: 19130409
    [No Abstract]   [Full Text] [Related]  

  • 4. Are multiple biomarker testing strategies ready for prime time in heart failure?
    Lee DS; Tu JV
    Circ Heart Fail; 2009 Sep; 2(5):387-8. PubMed ID: 19808366
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of b-type natriuretic peptide in heart failure management.
    Newton PJ; Betihavas V; Macdonald P
    Aust Crit Care; 2009 Aug; 22(3):117-23. PubMed ID: 19589695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of NT-pro BNP, left ventricular inotropic reserve and cardiopulmonary exercise test in patients with non-ischemic dilated cardiomyopathy.
    Parthenakis F; Patrianakos A; Nyktari E; Arfanakis D; Zacharis E; Vardas P
    Int J Cardiol; 2011 Mar; 147(2):326-8. PubMed ID: 21255848
    [No Abstract]   [Full Text] [Related]  

  • 7. B-type natriuretic peptide - a biomarker for all seasons?
    Mark DB; Felker GM
    N Engl J Med; 2004 Feb; 350(7):718-20. PubMed ID: 14960748
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in natriuretic peptides following passive containment surgery in heart failure patients with dilated cardiomyopathy.
    Bredin F; Liska J; Franco-Cereceda A
    Interact Cardiovasc Thorac Surg; 2009 Feb; 8(2):191-4. PubMed ID: 19008326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-type natriuretic peptide-a CPK for heart-failure and beyond (ischemia)?
    Arora V; Bhandari S
    Indian Heart J; 2006; 58(2):90-2. PubMed ID: 18989049
    [No Abstract]   [Full Text] [Related]  

  • 11. Congenital heart disease, exercise capacity and B-type natriuretic peptide.
    Carvalho VO
    Cardiol J; 2009; 16(5):489; author reply 490. PubMed ID: 19753535
    [No Abstract]   [Full Text] [Related]  

  • 12. [Natriuretic cardiac hormones. Clinical use in heart failure].
    Nielsen SJ; Gøtze JP; Raymond IE; Grønning BA; Kirk V; Bay-Nielsen M; Hildebrandt PR; Aldershvile J
    Ugeskr Laeger; 2004 Jan; 166(4):248-53. PubMed ID: 14964102
    [No Abstract]   [Full Text] [Related]  

  • 13. When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'?
    van Kimmenade RR; Pinto Y; Januzzi JL
    Eur Heart J; 2007 Dec; 28(24):2960-1. PubMed ID: 17984131
    [No Abstract]   [Full Text] [Related]  

  • 14. Biomarkers in heart failure management.
    Isaac DL
    Curr Opin Cardiol; 2008 Mar; 23(2):127-33. PubMed ID: 18303525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure.
    Tang WH; Francis GS; Morrow DA; Newby LK; Cannon CP; Jesse RL; Storrow AB; Christenson RH; Apple FS; Ravkilde J; Wu AH;
    Circulation; 2007 Jul; 116(5):e99-109. PubMed ID: 17630410
    [No Abstract]   [Full Text] [Related]  

  • 16. B-type natriuretic peptide: a universal cardiac biomarker?
    Teodorovich N; Krakover R; Vered Z
    Isr Med Assoc J; 2008 Feb; 10(2):152-3. PubMed ID: 18432033
    [No Abstract]   [Full Text] [Related]  

  • 17. Breathing not properly 10 years later: what we have learned and what we still need to learn.
    Maisel AS; Daniels LB
    J Am Coll Cardiol; 2012 Jul; 60(4):277-82. PubMed ID: 22813603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
    Felker GM; Hasselblad V; Hernandez AF; O'Connor CM
    Am Heart J; 2009 Sep; 158(3):422-30. PubMed ID: 19699866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Nikolaou M; Birmpa D; Farmakis D; Paraskevaidis I; Bistola V; Katsoulas T; Filippatos G; Kremastinos DT
    Am J Cardiol; 2009 Jan; 103(1):73-5. PubMed ID: 19101233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CA-125 - does this next biomarker have a chance to hope for an expectation of risk stratification in patients with heart failure?].
    Zieliński T
    Kardiol Pol; 2010 Jul; 68(7):779-80. PubMed ID: 20648435
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.